Key facts
- Nionyx’s last known valuation is $12.0M (Sep 2025).
- It has raised $4.0M; the latest was Seed Round ($4.0M) in Sep 2025.
- Notable investors include New York Ventures, 2048 Ventures, Empire State Development, AIN Ventures, Pathway Bioventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Nionyx
- ·The full record, as it builds
Funding rounds
No funding rounds for Nionyx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nionyx
Developer of precision gene therapies designed for kidney diseases. The company engineers targeted genetic treatments by optimizing capsid design, therapeutic cassettes, and delivery mechanisms to ensure safety and efficacy.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2025
- Website
- nionyxbio.com/
- Ownership
- Privately Held (backing)
Nionyx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nionyx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nionyx in its N-PORT filings yet. We sweep new filings monthly.